ABSTRACT
Recent investigations of the electric braking booster (E-Booster) focus on its potential to enhance brake energy regeneration. A vehicle's hydraulic system is composed of the E-Booster and electric stability control to control the master cylinder and wheel cylinders. This paper aims to address the independent closed-loop control of the position and pressure as well as the maintenance of the pedal feel. To track both the reference signals related to piston displacement and the wheel cylinder pressure, an explicit model predictive control (MPC) is developed. First, the new flow model is introduced as the foundation for controller design and simulation. Next, in accordance with the operational conditions, the entire system is divided into three switchable subsystems. The three distributed MPCs are constructed based on the linearized subsystems, and a state machine is used to perform the state jump across the controllers. A linear piecewise affine control law can then be obtained by solving the quadratic program (QP) of explicit MPC. Afterwards, the non-linear extended Kalman filter including the recorded time-variant process noise is used to estimate all the state variables. The effectiveness of the explicit MPC is evidenced by the simulations compared with a single MPC in regenerative and dead-zone conditions. The proposed controller decreases the latency significantly by 85 milliseconds, which also helps to improve accuracy by 22.6%. Furthermore, the pedal feel remains consistent, even when factoring in the number of vibrations caused by the inherent hydraulic characteristic of pressure versus volume.
ABSTRACT
Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens. This study (NCT03381742) retrospectively analyzed the data from 11 hospitals on 3,043 patients with coronary artery disease, who received C75QD, T90BID, ticagrelor 45 mg BID (T45BID), or ticagrelor 90 mg QD (T90QD). Compared with C75QD, both T45BID and T90QD showed significantly higher inhibition of platelet aggregation (P < .0001) and lower platelet-fibrin clot strength (P < .0001) induced by adenosine diphosphate. Furthermore, compared with T90BID, two low-dose regimens had a much lower minor bleeding rate and a significantly higher proportion of patients within the therapeutic window for P2Y12 receptor reactivity. There were no significant differences between T45BID and T90QD in the trough plasma concentrations of ticagrelor and its active metabolite. Similar efficacy and safety outcomes were observed in the propensity score-matched analysis. In conclusion, the low-dose ticagrelor regimen, either T45BID or T90QD, may provide a more attractive benefit-risk profile than C75QD or T90BID.
